Products
Tacatuzumab Biosimilar Antibody-Drug Conjugate for Research
Cat No.: GMP-Bios-INN-1406
Anti-Alpha Ferroprotein therapeutic antibody (Pre-made Tacatuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tacatuzumab (development code IMMU-105) is a humanized monoclonal antibody-drug conjugate targeting alpha-fetoprotein (AFP). It is developed by Immunomedics for liver cancer in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1406-1mg | 1mg | 4635 |
| GMP-Bios-INN-1406-10mg | 10mg | |
| GMP-Bios-INN-1406-100mg | 100mg | |
| GMP-Bios-INN-1406-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tacatuzumab biosimilar, Whole mAb ADC: Anti-Alpha Ferroprotein therapeutic antibody |
| INN Name | Tacatuzumab |
| Target | Alpha Ferroprotein |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2005 |
| Year Recommended | 2006 |
| Companies | Immunomedics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Liver cancer |
| Production | na |
| Development Tech | na |
